PMID- 7621576
OWN - NLM
STAT- MEDLINE
DCOM- 19950828
LR  - 20190813
IS  - 0300-0664 (Print)
IS  - 0300-0664 (Linking)
VI  - 42
IP  - 5
DP  - 1995 May
TI  - Fetal osteocalcin levels are related to placental 11 beta-hydroxysteroid 
      dehydrogenase activity in humans.
PG  - 551-5
AB  - OBJECTIVE: Overexposure to glucocorticoids in utero reduces birth weight and, in 
      animals, leads to persistent hypertension in the offspring. The fetus is normally 
      protected from maternal glucocorticoids by placental 11 beta-hydroxysteroid 
      dehydrogenase (11 beta-HSD) which catalyses the conversion of cortisol to inert 
      cortisone. In adult humans, osteocalcin is a sensitive marker of glucocorticoid 
      exposure. The aim of this study was to determine whether cord blood osteocalcin 
      levels were related to the ability of placental 11 beta-HSD to inactivate 
      maternal cortisol. DESIGN: Cross-sectional study examining the relation between 
      cord blood levels of osteocalcin and placental glucocorticoid metabolism at term. 
      PATIENTS: Twenty-one women attending for delivery at the Simpson Memorial 
      Maternity Pavilion in Edinburgh had cord venous and arterial blood samples 
      collected at delivery. MEASUREMENTS: Cord plasma levels of osteocalcin, cortisol 
      and cortisone were measured by radioimmunoassay and indices of placental 11 
      beta-HSD activity were calculated. RESULTS: All indices of placental 11 
      beta-hydroxysteroid dehydrogenase activity correlated directly and significantly 
      with cord blood osteocalcin levels. For cord blood osteocalcin and the placental 
      11 beta-HSD Activity Index, Pearson's r was +0.58, r2 = 0.33 and P < 0.02. 
      CONCLUSION: We conclude that term cord blood osteocalcin level reflects the 
      effectiveness of placental glucocorticoid inactivation, and may be a marker for 
      the development of adult hypertension.
FAU - Benediktsson, R
AU  - Benediktsson R
AD  - University Department of Medicine, Western General Hospital, Scotland, UK.
FAU - Brennand, J
AU  - Brennand J
FAU - Tibi, L
AU  - Tibi L
FAU - Calder, A A
AU  - Calder AA
FAU - Seckl, J R
AU  - Seckl JR
FAU - Edwards, C R
AU  - Edwards CR
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Biomarkers)
RN  - 104982-03-8 (Osteocalcin)
RN  - EC 1.1.- (Hydroxysteroid Dehydrogenases)
RN  - EC 1.1.1.146 (11-beta-Hydroxysteroid Dehydrogenases)
RN  - V27W9254FZ (Cortisone)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - 11-beta-Hydroxysteroid Dehydrogenases
MH  - Biomarkers/blood
MH  - Cortisone/blood
MH  - Cross-Sectional Studies
MH  - Female
MH  - Fetal Blood/*chemistry
MH  - Humans
MH  - Hydrocortisone/*metabolism
MH  - Hydroxysteroid Dehydrogenases/*metabolism
MH  - Hypertension/blood
MH  - Osteocalcin/*blood
MH  - Placenta/*enzymology
MH  - Pregnancy
MH  - Prognosis
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
AID - 10.1111/j.1365-2265.1995.tb02676.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 1995 May;42(5):551-5. doi: 
      10.1111/j.1365-2265.1995.tb02676.x.